<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093118</url>
  </required_header>
  <id_info>
    <org_study_id>TCP-TMI-7007</org_study_id>
    <nct_id>NCT01093118</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TMI-358 in the Treatment of Distal Subungual Onychomycosis of the Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Talima Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Talima Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a local treatment is effective for the treatment
      of toenail fungus (distal subungual onychomycosis).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rates</measure>
    <time_frame>48 weeks</time_frame>
    <description>Based on clinical evaluations (nail measurements, KOH, and mycological culture for dermatophytes), cure categories will be defined as either mycological cure, clinical cure, complete cure, or effective treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Distal Subungual Onychomycosis</condition>
  <arm_group>
    <arm_group_label>TMI-358</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMI-467</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMI-358</intervention_name>
    <description>Micro implant monthly x 3</description>
    <arm_group_label>TMI-358</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMI-467</intervention_name>
    <description>Micro implant monthly x 3</description>
    <arm_group_label>MMI-467</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 75 years of age, inclusive

          -  Diagnosed with distal subungual onychomycosis (DSO) of the toenails

          -  Great toe(s) with intact skin and intact neurologic functions

          -  Great toenail(s) free of nail polish

          -  At least one target great toe which has:

               -  25 to 75% involvement of the area of the nail unit (including destroyed or
                  missing parts of the nail plate)

               -  at least 2 mm of uninvolved nail growth as measured from the proximal nail fold
                  to the most proximal point to the disease process and with no lunular involvement

               -  nail unit hyperkeratosis at the most distal edge which measures no greater than 3
                  mm

               -  a positive KOH and culture

        Exclusion Criteria:

          -  Any significant disease of the hepatic, renal, endocrine (including diabetes
             mellitus), immune systems, or other health conditions which could interfere with or
             confound the results of study assessments

          -  Pre-existing chronic foot pain, neurologic deficit or skin disease/injury in treated
             foot

          -  In the case of female subjects, are pregnant, nursing, or planning to become pregnant
             within the study period

          -  History of clinically significant abnormal laboratory values, including liver function
             test results equal to or greater than 2 x the upper limit of normal

          -  Disease-like psoriatic toenails, significant toenail abnormalities/dystrophies,
             toenail injuries or any other condition in the toenail which could interfere with
             study evaluations (e.g., prevent obtaining normal appearing nail, after clearing of
             onychomycosis, due to chemical damage, genetic or pigmentary disorders, etc.)

          -  Have white superficial onychomycosis, proximal subungual onychomycosis, yellow spikes,
             or dermatophytoma

          -  Have paronychia

          -  Have a history of chronic alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J&amp;S Studies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Noss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Matheson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Medical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Swinyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacy Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Therapeutics Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norman Bystol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Mendez, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Dermatology Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>January 14, 2011</last_update_submitted>
  <last_update_submitted_qc>January 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Martin Babler</name_title>
    <organization>Talima Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>Distal subungual onychomycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

